Results 91 to 100 of about 165,965 (304)

Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions

Clinical Pharmacology &Therapeutics, EarlyView.
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects.
Maria J. Alfonso Arvez, Sam Wade, Darshna Goordeen, Jenni Ilomäki, Amanda J. Cross, Monica Langiu, George S. Q. Tan   +6 more
wiley   +1 more source

GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research

The Journal of Clinical Investigation
Cancer diagnoses are prevalent in people with obesity and type 2 diabetes, and abundant clinical evidence supports the protective effects of weight loss for cancer prevention.
Estefania Valencia-Rincón, Rajani Rai, Vishal Chandra, Elizabeth A. Wellberg   +3 more
doaj   +1 more source

Research hotspots and trends of GLP-1 receptor agonists in the treatment of Parkinson’s disease: a bibliometric analysis

Frontiers in Neuroscience
BackgroundPD is still managed symptomatically with levodopa, and no disease-modifying therapy is available, making effective treatment difficult. In recent years, preclinical and some clinical evidence have shown that glucagon-like peptide-1 receptor ...
Ting Yu, Ting Yu, Qingxin Mai, Qingxin Mai, Qingxin Mai, Qian Wang, Mingxia Pan, Yuanfang Xiong, Lingyu Kuang, Hanjiao Liu, Hanjiao Liu, Hanjiao Liu   +11 more
doaj   +1 more source

Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity

JAMA Health Forum
This economic evaluation estimates the 10-year net fiscal impact of expanded Medicare coverage for glucagon-like peptide-1 (GLP-1) receptor agonists for obesity treatment.
Jennifer H Hwang, N. Laiteerapong, Elbert S. Huang, D. Mozaffarian, A. M. Fendrick, David D. Kim   +5 more
semanticscholar   +1 more source

Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory Pathways

Clinical Pharmacology &Therapeutics, EarlyView.
Precision medicine offers the opportunity to improve the benefit–risk profile of new therapies by prospectively identifying patients most likely to respond or least likely to experience harm; however, its systematic integration into drug development remains inconsistent outside oncology.
Ingrid Holst‐Laubjerg, José M.A. Moreira   +1 more
wiley   +1 more source

Impact of Glucagon-like Peptide-1 Receptor Agonists on Intestinal Epithelial Cell Barrier

European Pharmaceutical Journal
While many types of diabetes medications are currently available, orally administered formulations of glucagon-like peptide-1 (GLP-1) receptor agonists have recently been launched. Therefore, gastrointestinal epithelial cells will be increasingly exposed
Takizawa Y., Kato A., Onsui A., Kanatanai S., Ishimura A., Kurita T., Nakajima T.   +6 more
doaj   +1 more source

Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus [PDF]

Pharmacia
In recent years, incretin mimetics have become an important part of type 2 diabetes mellitus therapy. The aim of this study is to evaluate the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists.
Lora Petrova, Kalina Andreevska, Iva Parvova, Valentina Petkova   +3 more
doaj   +3 more sources

GLP‐1 Receptor Agonism Exacerbates Activity‐Based Anorexia in Mice

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists reduce food intake and body weight, suggesting they should be avoided in anorexia nervosa. However, preclinical evidence that these drugs reduce activity and reward‐seeking behavior raises the possibility that they might attenuate the compulsive‐like hyperactivity central to ABA ...
Amit Thakar, Travis E. Brown, Shane T. Hentges   +2 more
wiley   +1 more source

Socioeconomic and Demographic Inequalities in Off-Label Prescription of Glucagon-Like Peptide-1 Receptor Agonists: A Swedish Descriptive Cohort Study

Obesity Facts
Introduction: In Sweden, glucagon-like peptide-1 (GLP-1) receptor agonists are subsidized for diabetes indication but not for obesity. Unregulated off-label prescription of GLP-1 receptor agonists for obesity treatment may raise concerns about
Laura Pazzagli, Ylva Trolle Lagerros
doaj   +1 more source

GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder

Endocrinology
Glucagon-like peptide-1 (GLP-1) is abundant in the circulation, and it is well-known to regulate glucose homeostasis, feeding, and body weight. GLP-1 receptor agonists are therefore approved for treating type 2 diabetes and obesity.
E. Jerlhag
semanticscholar   +1 more source